Concepts (74)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metformin | 3 | 2024 | 35 | 0.580 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 8 | 0.430 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 27 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 72 | 0.410 |
Why?
|
| Urticaria | 1 | 2013 | 2 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 92 | 0.400 |
Why?
|
| Neutrophils | 1 | 2013 | 14 | 0.390 |
Why?
|
| Inflammation | 1 | 2013 | 143 | 0.360 |
Why?
|
| Ivermectin | 3 | 2024 | 3 | 0.290 |
Why?
|
| Fluvoxamine | 3 | 2024 | 4 | 0.290 |
Why?
|
| Adult | 8 | 2025 | 2113 | 0.280 |
Why?
|
| Middle Aged | 6 | 2025 | 2108 | 0.270 |
Why?
|
| Young Adult | 4 | 2025 | 567 | 0.250 |
Why?
|
| Buprenorphine | 1 | 2025 | 4 | 0.240 |
Why?
|
| Naloxone | 1 | 2025 | 22 | 0.240 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 29 | 0.240 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 17 | 0.230 |
Why?
|
| Humans | 10 | 2025 | 6794 | 0.230 |
Why?
|
| Safety-net Providers | 1 | 2025 | 24 | 0.230 |
Why?
|
| Female | 7 | 2025 | 4060 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 49 | 0.230 |
Why?
|
| Viral Load | 1 | 2024 | 26 | 0.220 |
Why?
|
| Antiviral Agents | 1 | 2024 | 53 | 0.210 |
Why?
|
| Tobacco Use Disorder | 1 | 2023 | 10 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2023 | 25 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 153 | 0.190 |
Why?
|
| Male | 6 | 2025 | 3671 | 0.190 |
Why?
|
| Double-Blind Method | 3 | 2024 | 101 | 0.150 |
Why?
|
| Adolescent | 3 | 2014 | 869 | 0.120 |
Why?
|
| HIV Infections | 2 | 2014 | 432 | 0.120 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2014 | 1 | 0.110 |
Why?
|
| India | 1 | 2014 | 13 | 0.110 |
Why?
|
| Dermatology | 1 | 2014 | 9 | 0.110 |
Why?
|
| Sex Workers | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cities | 1 | 2014 | 7 | 0.110 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2014 | 15 | 0.110 |
Why?
|
| Condoms | 1 | 2014 | 41 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2014 | 100 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 2013 | 12 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 280 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 79 | 0.100 |
Why?
|
| Pregnancy | 2 | 2023 | 599 | 0.080 |
Why?
|
| Aged | 2 | 2024 | 1539 | 0.070 |
Why?
|
| Sex Work | 1 | 2008 | 10 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 102 | 0.060 |
Why?
|
| Opiate Substitution Treatment | 1 | 2025 | 3 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2025 | 9 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2025 | 34 | 0.060 |
Why?
|
| Los Angeles | 1 | 2025 | 321 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2023 | 7 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 10 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 40 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 49 | 0.050 |
Why?
|
| Incidence | 1 | 2023 | 197 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 17 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 37 | 0.050 |
Why?
|
| Overweight | 1 | 2022 | 30 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2023 | 500 | 0.040 |
Why?
|
| Nicotine | 1 | 2023 | 144 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 497 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 226 | 0.040 |
Why?
|
| Mozambique | 1 | 2014 | 1 | 0.030 |
Why?
|
| Administrative Personnel | 1 | 2014 | 3 | 0.030 |
Why?
|
| Drug Users | 1 | 2014 | 4 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 43 | 0.030 |
Why?
|
| Counseling | 1 | 2014 | 29 | 0.030 |
Why?
|
| Health Personnel | 1 | 2014 | 49 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2008 | 13 | 0.020 |
Why?
|
| Urban Health | 1 | 2008 | 20 | 0.020 |
Why?
|
| Focus Groups | 1 | 2008 | 46 | 0.020 |
Why?
|
| South Africa | 1 | 2008 | 68 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2008 | 77 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2008 | 82 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 85 | 0.020 |
Why?
|